The cell wall imparts structural strength and shape to bacteria. It is made up of polymeric glycan chains with peptide branches that are cross-linked to form the cell wall. The cross-linking reaction, catalyzed by transpeptidases, is the last step in cell wall biosynthesis. These enzymes are members of the family of penicillin-binding proteins, the targets of ␤-lactam antibiotics. We report herein the structure of a penicillin-binding protein complexed with a cephalosporin designed to probe the mechanism of the cross-linking reaction catalyzed by transpeptidases. The 1.2-Å resolution x-ray structure of this cephalosporin bound to the active site of the bifunctional serine type D-alanyl-D-alanine carboxypeptidase͞ transpeptidase (EC 3.4.16.4) from Streptomyces sp. strain R61 reveals how the two peptide strands from the polymeric substrates are sequestered in the active site of a transpeptidase. The structure of this complex provides a snapshot of the enzyme and the bound cell wall components poised for the final and critical cross-linking step of cell wall biosynthesis.
S
ince their clinical introduction more than 50 years ago, ␤-lactam antibiotics have been essential drugs in combating bacterial infections. To date, ␤-lactams constitute approximately 60% of all clinically used antibiotics. These antibiotics interfere with cell wall biosynthesis. All bacteria, with very few exceptions, have a cross-linked cell wall (1, 2) . The cross-linking takes place as the last step in biosynthesis of cell wall, a reaction that is catalyzed by bacterial transpeptidases (1, (3) (4) (5) (6) , enzymes that rely on an active-site serine for their reactions. The activated serine of transpeptidase attacks the carbonyl of the penultimate D-Ala of the peptidoglycan precursor, with concomitant departure of the terminal D-Ala, to give rise to an acyl-enzyme intermediate (Fig. 1A ). An amine from the side chain of another peptidoglycan (diaminopimelate, modified lysine, or ornithine derivative) reacts with the ester of the acyl-enzyme intermediate to give the cross-linked species.
It was suggested by Tipper and Strominger (7) that a ␤-lactam antibiotic, such as a penicillin or a cephalosporin, mimics the conformation of the acyl-D-Ala-D-Ala portion of the bacterial peptidoglycan. It also was found that ␤-lactam antibiotics covalently modify the active-site serine of transpeptidase via the ␤-lactam carbonyl group, which spatially corresponds to the carbonyl of the penultimate D-Ala of the pentapeptide. The penicillin structure in its entirety remains tethered to the enzyme as an integral part of the long-lived acyl-enzyme species, presenting a steric barrier to the approach of the second strand of peptidoglycan at the ester carbonyl (8) . With the active site covalently modified by the antibiotic, the enzyme is no longer available for its normal function, transpeptidation is prevented, and bacterial death ensues.
We designed and synthesized cephalosporin 1, which incorporates components of the cell wall in its structure (Fig. 1B) . We envisioned that cephalosporin 1 would modify the active-site serine of the transpeptidase, as would other ␤-lactams, by mimicking the acyl-D-Ala-D-Ala portion of the peptidoglycan (the portions of 1 in red in Fig. 1B) . But, the portion to the right of the acylated species with our cephalosporin (in green; complex 2, Fig. 1B ) would mimic the approaching nucleophile, diaminopimelate, from the second strand of the peptidoglycan. Hence, cephalosporin 1 was expected to be an inhibitor of transpeptidases, albeit a unique one with structural characteristics of the two strands of peptidoglycan. Complex 2 represents a snapshot of the two peptidoglycan strands just before the cross-linking reaction, when diaminopimelate from the second strand approaches the ester of the acyl-enzyme intermediate formed by the transpeptidase bound to the first strand of peptidoglycan. Although there are some variations in the structures for the cross-links of peptidoglycans in different types of bacteria, the structure of peptidoglycan that is incorporated into cephalosporin 1 is seen for all Gram-negative bacteria and occurs in many Gram-positive organisms (1) . Therefore, the mechanistic conclusions drawn from complex 2 would be valid for the majority of bacteria. We hasten to add that the two ''strands of peptidoglycan'' would be tethered to each other in complex 2. It turns out that this reduction in the degrees of freedom for the two strands is absolutely necessary for the structure determination, in light of the fact that numerous attempts at binding derivatives of peptidoglycan into the PBP active sites have so far failed to reveal any structural information. We report herein the synthesis of cephalosporin 1, the complex of a transpeptidase modified by 1 and its mechanistic implications for the crosslinking of the bacterial cell wall.
Methods
The synthetic procedures for the preparation of cephalosporin 1 and each of the intermediates, and their characterization by high-field 13 C and 1 H NMR, IR, and high-resolution mass spectra can be found in the supplemental material and Tables 2  and 3 , which are published on the PNAS web site, www.pnas.org. All compounds containing the oxazolidine moiety exhibited two sets or broadening of NMR signals at room temperature, due to the presence of a dynamic equilibrium between two conformers in solution in the absence of enzyme (9, 10) . Additionally, compounds with peptide chains attached to the cephalosporin moiety also exhibited additional conformers. These conformational states were studied either by recording the spectra at higher temperatures or by reducing the concentration to minimize such conformational states that may be induced in an intermolecular set of interactions.
Crystallization and Refinement. A 0.30 ϫ 0.20 ϫ 0.15-mm native R61 DD-peptidase͞transpeptidase cr ystal (space group P2 1 2 1 2 1 , cell dimensions a ϭ 51.8, b ϭ 66.4, and c ϭ 100.1 Å, one 37.5-kDa molecule per asymmetric unit) was soaked for 4 days in a 30 mM solution of cephalosporin 1, 28% PEG-8000, 50 mM sodium phosphate at pH 6.8. The crystal then was dipped in cryoprotectant, made up of the soak solution plus 20% glycerol, and f lash-cooled in a nitrogen gas stream. Data were collected at beamline X12C of the National Synchrotron Light Source at Brookhaven National Laborator y, Brookhaven, New York and processed by using HKL (11) .
Initial refinement was carried out by using CNS (12) . The refined model was fitted to 2 F o ϪF c and F o ϪF c electron density maps by using CHAIN (13) . Several rounds of refinement and fitting were performed. Solvent molecules, with reasonable hydrogen bond distances and geometry, were added except in the region of the ligand-binding site. The agreement between the model of the complex and the diffraction data are measured by the R factor, which converged in CNS to 0.214. After CNS refinement, SHELX-97 (14) was used to refine the molecule anisotropically, which resulted in a 0.035 drop in R free , an independent measure of the progress of the refinement. The program O (15) was used to analyze and fit electron density maps from SHELX-97. At this stage, the ligand and alternate side-chain conformations were added. When the R factor converged in SHELX-97, hydrogen atoms were added that appeared as 3-difference density peaks.
Energy Minimizations and Molecular Dynamics Simulations. Energy minimizations and molecular dynamics simulations were performed by using the AMBER 5.0 suite of software (16, 17) . Graphical and molecular database analyses were performed by using the SYBYL software (version 6.5, Tripos Associates, St. Louis). For cephalosporin 1 and for all other residues, MNDO electrostatic potential charges and standard AMBER parameter set were used, respectively. Carbohydrate residues, Nacetylglucosamine and N-acetylmuramic acid (NAM), were treated by using the GLYCAM force field parameter set (18) . The 1.2-Å resolution crystal structure of the Streptomyces R61 PBP complexed with the cephalosporin 1 was used for the starting coordinates. Initially, the protein molecule and its crystallographic symmetry counterpart, including the crystallographic water molecules, were solvated with 25,692 TIP3 waters and subjected to energy minimization for 5,000 iterations. Subsequently, molecular dynamics simulations were carried out on the assembly at constant volume for 10 ps at 300 K in the time steps of 2 fs by using periodic boundary conditions. The system was then further equilibrated at constant pressure of 1 atm for 40 ps at 300 K by using periodic boundary conditions with nonbonded cut-off of 12 Å. After 50 ps, snapshots of the molecular dynamics simulations were collected at every picosecond for up to 248 ps. The average rms deviation of C ␣ atoms was 1.28 Ϯ 0.18 Å. Coordinates of the energy-minimized inhibitor in the presence and absence of the symmetry-related protein molecule were extracted and overlapped to compare the conformational differences. from Streptomyces sp. strain R61 readily, because incubation of cephalosporin 1 and the enzyme in crystalline form gave a stable acyl-enzyme species that was detectable by using x-ray crystallographic techniques. The position of cephalosporin 1 in the active site was determined by fitting 1.2-Å difference electron density maps. Statistics for the data collection and refinement show that this is a well-determined structure (Table 1) . Fig. 2A shows the details of binding of cephalosporin 1 in the active site pocket of the enzyme, for which a schematic is presented in Fig. 2B . Cephalosporin 1 is bound between the all-helical and the ␣͞␤ domains of the PBP. PBPs have three signature sequences with eight conserved residues: Ser 62 -x-xLys, which contains the catalytic serine residue; Ser͞Tyr 159 -xAsn, on a loop below the active site; and Lys͞His 298 -Thr-GlyThr͞Ser, which occurs on the inner strand of the ␤-sheet that flanks the active site. Both strands 1 and 2 of cephalosporin 1 are oriented antiparallel to the inner ␤-strand of the antiparallel ␤ sheet of the enzyme. The catalytic serine residue is somewhat buried in a pocket formed below the grooves on the surface of the enzyme, where the bulk of the peptidoglycan analogs bind. The strands are anchored by 11 hydrogen bonds in the acylated enzyme species, five associated with strand 1 and six associated with strand 2. Seven of these interactions involve residues that are conserved in all known PBPs (see Fig. 2 ).
Results and Discussion
Several key features are revealed by the structure of the complex. Serine-62 is positioned on a helix dipole, and it is likely that the pKa of its side-chain hydroxyl is somewhat lowered. The side chain of Lys-65 is in contact with the Ser-62 hydroxyl (3.04 Å) in the absence of any ligand and it is believed to activate it for the enzyme acylation event (5, 8) . The N of the diaminopimelate (DAP) surrogate in the inhibitor is located on the ␤-side of the ␤-lactam, 2.6 Å from the carbonyl of the ester bond linking the compound to the enzyme. This positioning is ideally suited for the subsequent addition to the ester carbonyl that would result in the natural cross-linked cell wall. Tyrosine-159, assuming that its side chain is deprotonated, is the likely active-site base positioned for activation of the incoming DAP amine (at 4.0 Å) for the addition reaction. The DAP amine, Tyr-159, and Lys-65 could function as a relay mechanism for transfer of a proton from the incoming peptidoglycan to the departing Ser-62.
Crystallographic studies have shown little change in the enzyme structure on binding ␤-lactams. One exception is the side chain of Thr-301, which rotates to hydrogen bond with a side-chain nitrogen in bulky cephalosporins (8) . This rotation also is observed with cephalosporin 1. Interestingly, with cephalosporin 1 there is also an unusual rotation of the ␤-sheet carbonyl of Thr-301, moving it 3.3 Å away from the active site. This movement is no doubt necessary for steric reasons to allow proper positioning of the peptidoglycan analog. The only other shift of the enzyme to accommodate the ligand is a movement of the side chain of Asn-161, which moves into a hydrogenbonding orientation, with N␦2 positioned 2.9 Å from the oxygen of the C-7 side-chain amide of cephalosporin 1.
Crystal packing positions a second copy of the enzyme molecule near the active site of the first, and three interactions occur between the bound ligand and the symmetry-related copy of the enzyme. One interaction is a strong hydrogen bond (2.7 Å) between oxygen of the side chain in D-Glu of cephalosporin 1 and the main-chain amide of Asp-98 on the symmetry-related molecule. The other two contacts are at distances of 3.7 and 3.3 Å, representing weak interactions. The effect of this symmetryrelated copy of the enzyme on binding of cephalosporin 1 was investigated by using molecular dynamics simulations. No difference in binding of cephalosporin 1 was observed with or without the inclusion of the symmetry-related copy of the enzyme molecule. Within the simulation period of 198 ps (after equilibration), the inhibitor in both situations behaved similarly. The average rms deviations of all of the atoms of the cephalosporin inhibitor in the presence and absence of the symmetryrelated enzyme molecule were 1.62 Ϯ 0.41 and 1.49 Ϯ 0.80 Å, respectively. This shows that the movement of cephalosporin 1 after acylation of the active site serine residue is not influenced by the inclusion of the symmetry-related enzyme molecule. Therefore, the structure depicts a realistic conformation, unaffected by crystallographic packing.
In solving the structure of this complex, we were able to consider the position of the polysaccharide portions of the cell wall. We have extended the structures of the peptidoglycan portions from the crystallographically determined positions for cephalosporin 1 up to NAM-N-acetylglucosamine (NAG) res- idues of the peptidoglycan strands. Eight crystallographic water molecules were removed in building the extensions onto the x-ray structure of cephalosporin 1. The model of the crystallographic structure with the NAG-NAM extensions was solvated and energy-minimized by using the AMBER 5.0 package. Energy minimization showed stable glycan strands aligned in welldefined grooves on the surface of the enzyme (Fig. 2C ). These hydrophilic grooves, which are 18 Å apart at the peptide branching points in NAM, would accommodate the polymeric backbone of the sugar residues in peptidoglycan. We note that Pares et al. (19) built a model of the peptidoglycan into the active site of their 3.5-Å resolution structure of the PBP2x from Streptococcus pneumoniae. Although a direct comparison of their model and ours is not entirely possible, it is clear that the putative saccharide-binding grooves in that report do not agree with the positioning developed in our work.
There is mechanistic and structural evidence that ␤-lactamases, enzymes that confer resistance to ␤-lactam antibiotics, evolved from PBPs (5, 20, 21) . The two classes of enzymes have similar overall structural folds, yet neither can effectively catalyze the reaction of its kin. The structure of Fig. 2C reveals why this is the case. The groove that accommodates peptidoglycan strand 2 is obliterated by an insertion in ␤-lactamases (residues 214-224 and 285-296 in class A and class C ␤-lactamases, respectively) at that site. It is interesting that the local folds for the two peptide insertions are distinct in the two classes of ␤-lactamases. Hence, it would appear that nature adopted this ploy on two separate occasions in evolution of ␤-lactamases to prevent interactions with strand 2 of peptidoglycan. Class A and C ␤-lactamases are known to have descended from different PBPs (5), so these independent evolutionary adaptations are plausible. Furthermore, the surface of the transpeptidase that interacts with peptidoglycan strand 1 (at six o'clock in Fig. 2C ) is entirely absent in the two classes of ␤-lactamases. Therefore, ␤-lactamases have lost the structural surface for binding to both peptidoglycan strands, so as to be able to specialize exclusively as enzymes of antibiotic resistance.
These structural studies show the positions of the peptidoglycan components poised for the cross-linking step of cell wall biosynthesis, providing a unique glimpse of how this critical step takes place in bacteria. These data, together with the extension of the crystallographic structure to model the glycan positions, provide valuable information to aid in the design of novel antibacterials that would bind to these enzymic subsites.
